ArcaScience is a Paris-based AI healthtech company founded in 2018 to deliver AI-powered benefit-risk assessment, making drug development faster, more reliable, and ultimately safer for patients. During the COVID-19 crisis, ArcaScience was selected by the French government to structure and deliver the complete scientific corpus on the virus: an early validation of the platform’s scientific rigor at scale.

The company has reached break-even twice since late 2024. In 2025, ArcaScience closed a $7 million seed round led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technologies. Later that year, ArcaScience Inc. was established as a US subsidiary to support its American expansion.

Today, ArcaScience’s flagship Benefit-Risk Assessment platform is in active use and has been applied to data covering over 70,000 patients, with global pharmaceutical leaders including Sanofi, AstraZeneca, GSK, and Takeda, cutting months of manual review down to days and producing fully sourced, auditable, and regulator-ready outputs. ArcaScience is building toward a future where its platform defines how the industry approaches benefit-risk assessment.

The ArcaScience Benefit-Risk Assessment platform integrates 24 specialized AI models trained on over 100 billion biomedical data points, drawn from clinical trial results, peer-reviewed literature, pharmacovigilance databases, and real-world patient records. The platform can also integrate clients’ own private datasets, keeping proprietary data fully within their local environment. Every assessment is fully sourced and traceable, eliminating the hallucinations and unsupported conclusions that make most AI tools unsuitable for regulated pharmaceutical environments. Using this platform enables clinical teams to move faster through regulatory submissions, reduce late-stage trial failures, and make benefit-risk decisions with genuine confidence.